News

RPG Life Sciences Has Launched India's First Naproxen-Esomeprazole Combination — A Drug That Treats Pain and Protects the Stomach at the Same Time

By Mustafa Shariff, Editor in Chief · July 23,2026 · 2 mins read

Mustafa Shariff, Editor in Chief — RPG Life Sciences Has Launched India's First Naproxen-Esomeprazole Combination — A Drug That Treats Pain and Protects the Stomach at the Same Time

Summary

  • RPG Life Sciences Launches India's First Naproxen-Esomeprazole Combination: Pain Relief With Built-In Stomach Protection
  • RPG Life Sciences, in partnership with Archerchem, has launched India's first Naproxen-Esomeprazole fixed-dose combination — providing pain relief and gastroprotection in a single tablet for Indian patients.

"Through our partnership with RPG Life Sciences, we are proud to deliver incremental innovation that enhances medication adherence and brings meaningful benefits to patients across India. Naproxen's established efficacy in musculoskeletal conditions, combined with Esomeprazole's proven gastroprotective profile, creates a clinically rational, patient-centric combination that addresses a real-world problem physicians face every day."

RPG Life Sciences has announced a partnership with Archerchem for the launch of what is described as India's first Naproxen-Esomeprazole fixed-dose combination — a single tablet that pairs one of India's most widely used non-steroidal anti-inflammatory drugs (NSAIDs) with a proton pump inhibitor (PPI) in a combination designed to provide both the pain relief and anti-inflammatory benefit of naproxen and the gastroprotective benefit of esomeprazole in a single co-administered formulation.
The clinical rationale for the combination is straightforward and well-established in international prescribing practice. Naproxen — marketed under RPG Life Sciences' established Naprosyn brand in India — is a widely used NSAID for managing the pain, inflammation, and stiffness associated with musculoskeletal conditions including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute musculoskeletal injuries. NSAIDs as a class are highly effective analgesic and anti-inflammatory agents, but their mechanism of action — inhibition of cyclooxygenase (COX) enzymes that produce prostaglandins — also suppresses the prostaglandins that maintain the protective mucus layer of the gastric mucosa. This creates a well-documented risk of NSAID-induced gastrointestinal complications: gastric irritation, gastric and duodenal ulcers, and GI bleeding.
The Clinical Problem This Combination Solves
The standard clinical practice for managing this NSAID gastroprotection problem has been to co-prescribe a PPI alongside the NSAID — one tablet for pain, one tablet for stomach protection. Esomeprazole, the S-enantiomer of omeprazole, is one of the most widely prescribed PPIs in India, highly effective at suppressing gastric acid secretion and preventing NSAID-induced gastrointestinal complications in at-risk patients. However, co-prescribing two separate tablets creates two specific clinical problems: medication adherence (patients taking the NSAID for pain relief and skipping the PPI because they are not in immediate pain from the stomach) and prescribing burden (physicians must remember to prescribe both components, and pharmacists must dispense both).
The Naproxen-Esomeprazole fixed-dose combination resolves both problems simultaneously: the gastroprotective PPI is physically co-packaged with the NSAID in a single tablet, ensuring that patients cannot take one without the other. This structural approach to adherence is the same rationale behind many of medicine's most successful fixed-dose combinations — most famously the HIV antiretroviral triple-combination tablets that transformed HIV treatment adherence globally.
Why This Is India's First
Naproxen-Esomeprazole fixed-dose combinations have been available in international markets for some years — most notably as Vimovo (marketed by AstraZeneca), which received FDA approval in 2010 and has been available in EU markets. The formulation uses a specific immediate-release esomeprazole layer combined with an enteric-coated naproxen core — a design that delivers the esomeprazole ahead of the naproxen to pre-emptively suppress gastric acid before the naproxen reaches the stomach.
India's complex regulatory environment for fixed-dose combinations — where the CDSCO requires separate review and approval for each FDC's clinical rationale — has historically slowed the entry of combination products that are already standard of care internationally. India's systematic FDC rationalisation programme (BHC Media has covered multiple rounds of FDC bans in 2026) has, perhaps counterintuitively, also created more rigorous scrutiny of new FDC submissions. The RPG Life Sciences-Archerchem combination's 'India first' designation reflects the regulatory pathway complexity that has delayed this clinically rational combination's availability in India compared to Western markets.
The Commercial Strategy
RPG Life Sciences plans to leverage the established brand equity of Naprosyn — its naproxen brand that has been marketed in India for many years — alongside its extensive physician engagement network to drive adoption. The combination will be promoted to super-specialists (rheumatologists, orthopaedic surgeons) and general practitioners who routinely prescribe NSAIDs for chronic pain and inflammatory conditions. The physician relationship depth that RPG Life Sciences has built through Naprosyn provides the commercial infrastructure for introducing the combination product to a pre-existing, receptive prescriber base.
BHC Perspective
At Bengaluru Health Community, the RPG Life Sciences-Archerchem Naproxen-Esomeprazole launch is a pharmaceutical product innovation story that illustrates an important dimension of India's pharmaceutical landscape: incremental innovation at the drug delivery and combination level creates clinically meaningful products even within mature therapeutic categories. For BHC founders in pharmaceutical formulation, drug delivery technology, or specialty pharma — the story of bringing an internationally proven combination to India for the first time through a regulatory pathway and commercial partnership model is exactly the kind of incremental innovation that the Indian pharma market still needs much more of.
Frequently Asked Questions
Q: What is RPG Life Sciences' new product?
A: India's first Naproxen-Esomeprazole fixed-dose combination — a single tablet pairing the NSAID naproxen (RPG's Naprosyn brand) with the PPI esomeprazole for gastroprotection, launched in partnership with Archerchem. Provides pain/anti-inflammatory benefit plus stomach protection in a single, co-administered tablet.
Q: Why combine Naproxen with Esomeprazole?
A: NSAIDs like naproxen suppress the prostaglandins that protect the gastric mucosa, causing a well-documented risk of gastric irritation, ulcers, and GI bleeding. Co-administering a PPI (esomeprazole) prevents this complication. A fixed-dose combination solves the adherence problem of patients taking the painkiller but skipping the stomach protector.
Q: Why is this India's first if it exists internationally?
A: Vimovo (naproxen-esomeprazole) received FDA approval in 2010 and has been available in Western markets for years. India's complex FDC regulatory environment — requiring separate CDSCO review and approval for each combination's clinical rationale — has historically delayed entry of internationally available combinations into the Indian market.